Objectives. HLA-
Introduction HLA-B27 is strongly associated with a group of inflammatory arthritic disorders collectively known as the SpA, typified by AS [1] . Theories for B27 disease involvement include presentation of arthritogenic peptides to CD8 T cells and induction of a proinflammatory misfolded protein response (reviewed in [2] ). B27 is expressed at the surface of antigen presenting cells (APCs) as classical b2m-associated class I heterodimers and disulphide-bonded b2m-FHC forms including homodimers (termed B27 2 ) [35] . We have proposed that disease results from B27 FHC immune receptor interactions promoting arthritis [6, 7] . Such immune receptors include members of the killer cell immunoglobulin-like receptor (KIR) and leukocyte immunoglobulin-like receptor (LILR) families.
HLA-B27 has multiple allelic variants [8] , with some alleles such as the prototypic dominant Caucasian HLA-B*27:05 subtype being strongly associated with disease while others such as HLA-B*27:09 are not associated [9] . Different B27 variants differ by one or more amino acid substitutions, frequently resulting in altered residues within their peptide binding clefts [10] . HLA-B*27:09 [11] is not associated with disease and differs from HLA-B*27:05 by one amino acid substitution. Aspartic acid at position 116, in the a1 domain, is substituted to a histidine (D116H).
KIR are expressed by NK cells and minor subsets of T cells [12] . B27 binds to KIR family members with three extracellular immunoglobulin-like domains (DoD1D2) and a long cytoplasmic tail termed KIR3DL1/2. KIR3DL1 recognizes HLA-class I molecules including HLA-B*27:05 that express the Bw4 epitope [13] . While both HLA-B*27:05 FHC and heterodimer bind to KIR3DL1, only FHC binds to KIR3DL2 [3, 14] . Although the sequence of peptide bound to class I heterodimers affects KIR3DL1 and KIR3DL2 recognition, by contrast, recombinant B27 homodimer binding to KIR is independent of complexed peptide [14] . KIR ligation inhibits activation-induced cell death (AICD) [15, 16] . Ligation of KIR3DL2 by B27 FHC promotes the survival of NK and Th17 cells [17, 18] . AS patients have increased proportions of activated Th17 and NK cells expressing KIR3DL2 [17, 18] .
The LILR receptors LILRB1 and LILRB2 bind a broad range of b2m-associated classical and non-classical class I [19] . LILRB2 but not LILRB1 binds to b2m-free class I heavy chain forms including HLA-B27 FHC and B27 dimer [20, 21] . While LILRB1 is broadly expressed on B cell, myeloid cells NK and T cells, LILRB2 is expressed by cells of myeloid origin.
We hypothesized that the differential association of HLA-B*27:09 with disease could be due to differences in its interaction with KIR and LILR immune receptors compared with HLA-B*27:05. Thus, we compared the formation of dimer and FHC by HLA-B*27:05 and HLA-B*27:09 and their interaction with KIR3DL1 and KIR3DL2. Our results suggest that differences in formation of FHC ligands for KIR3DL2 by HLA-B*27:05 and HLA-B*27:09 could play a role in the differential association of these alleles with AS.
Materials and methods

HLA-B27 plasmid constructs
Prokaryotic plasmids and PHR-SIN lentiviral cassettes for HLA-B*27:09 expression were generated by mutagenesis of pLM1-HLA-B*27:05 and PHR-SIN HLA-B*27:05, respectively, using the QuickChange site-directed mutagenesis kit (Invitrogen) following the manufacturer's instructions.
Lentiviral transduction of cell lines and immunoprecipitations
LBL.721.221 cells (hereafter referred to as 221 cells) were transduced with lentivirus expressing HLA-B*27:05 or HLA-B*27:09 as described previously [21] . 20 Â 10 6 parental 221 cells or 221B*27:05 and 221B*27:09 cells were surface biotinylated with NHS-LC-biotin (Thermoscientific UK Ltd) according to the manufacturers instructions. Subsequently cells were stained with HC10 or W632 antibody (10mg), washed with ice-cold PBS and lysed as previously described [14] . Lysates were precipitated with anti-mouse immunoglobulins Dynabeads, resolved by non-reducing or reducing SDS-PAGE and western blots developed with streptavidin-HRP (Sigma) or HRP-conjugated HC10.
KIR3DL2CD3e reporter cell assay
Jurkat T cell reporter cells transduced with a KIR3DL2CD3e lentiviral expression cassette were prepared as previously described [22] . All experiments for cytokine assay were set up in RPM1640 medium (Sigma) supplemented with 10% fetal calf serum and antibiotics [14] . 200 000 transduced T cells were incubated with 200 000 parental 221 cells or HLA-B*27:05 or HLA-B*27:09 transduced 221 cells for 24 h in with/without HC10, W632, ME1 or isotype control IgG1/G2a mAbs (MOPC 123 and MG1-45; Biolegend) at 50 mg/ml. Subsequently, supernatants were harvested for IL-2 ELISA according to the manufacturer's instructions (EBiosciences Ltd UK).
Recombinant protein and tetramer generation HLA-B27 heterodimer and homodimer were expressed and produced as previously described [3] . Recombinant biotinylated HLA-G dimers were prepared as previously described [20] . Yields of refolded protein were calculated by FPLC peak integration using the Unicorn software. HC10 and HD6 ELISAs were performed as described previously [23] . Shared HLA-B*27:05 and HLA-B*27:09 peptides used in this study: NRIKGIPKL; GRIGPNIRL; ARLQTALLV and RRFFPYYVY [24] ; and RRRWRRLTV [25] . HLA-B*27:05 peptides: RRIYDLIEL [26] ; KRWIILGLNK (GAG, [27] ). SRYWAIRTR (Flu NP [28] ) HLA-B*27:09 peptides: TRIPKIQKL [24] . Proteins were biotinylated and tetramers made with extravidin PE (Sigma) as previously described [14] .
www.rheumatology.oxfordjournals.org Tetramer staining Tetrameric complexes were used to stain Baf3 cells transfected with KIR3DL1, KIR3DL2, LILRB1 or LILRB2 receptor as previously described [14] .
Generation of NK cell lines KIR3DL2+ NK cell lines were FACS-sorted from PBMC using the DX31 mAb (Gift from Jo Phillips, DNAX), and maintained by allogeneic stimulation as previously described [17] .
Coculture of NK cell lines with HLA-B27-expressing APCs NK cell lines were labelled with CFSE according to the manufacturer's instructions (Invitrogen). 100 000 500 0000 g-irradiated 221 APCs were incubated with equal numbers of NK cells as previously described [17] . On day 5 cells were first stained for KIR3DL2 expression and then stained with allophycocyanin-conjugated Annexin V (BD Biosciences) and pacific blue Live-Dead stain (Invitrogen) according to the manufacturer's instructions.
Patients and controls
18 HLA-B*27:05 AS patients (12 males and 6 females, mean age 42.8 ± 8.2 years, mean disease duration 17.1 ± 11 years), 12 HLA-B*27:05 (mean age 35.8 years), 12 HLA-B*27:09 (mean age 37.5 years) and 8 HLA-B27 negative (mean age 36.6 years), sex-matched healthy controls (HCs), were recruited under written informed consent. All patients fulfilled the modified New York criteria for Ankylosing Spondylitis and were not on anti-TNF-a drugs at the time of taking samples. All patients and HCs selected for this study were of Sardinian Caucasian origin dating back at least three generations from both the maternal and paternal side. This study was approved by the Institutional Ethical Committee of the University Hospital, Cagliari, Italy (365/09/CE).
Reagents and antibodies
KIR3DL2 or KIR3DL1 expression was detected by indirect staining with DX31 MAb or DX9 MAbs (Biolegend) then Fluorescein isothiocyanate-conjugated goat F(ab')2 anti-mouse (GAM) IgG (F0479, DAKO). Cells were then stained with allophycocyanin-conjugated anti-CD56 (N901/NKH-1, Beckman Coulter, Fullerton, CA, USA), PerCP-conjugated anti-CD3 (SK7, BD Biosciences), PEanti-CD4 (SFCI12T4D11, Coulter) or PE-Cy7-anti-CD4 (BD Biosciences).
The specificities of anti-HLA class I antibodies used in this study are summarized in Table 1 . HD6 antibody binds to HLA-B27 dimers and multimers [23] . HC10 antibody recognizes a linear epitope in HLA class I A, B and C heavy chains incorporating amino acids 5564 of the heavy chain [29] . W6/32 recognizes a discontinuous epitope in the a2 and a3 domains of HLA-A, B and C incorporating residue 121 of heavy chain formed by both b2 m-associated and free forms of HLA class I [30, 31] . ME1 binds a conformational b2m-dependent epitope in the a1 domain of HLA-B27, critically dependent on interactions between residues 6771 [32] .
Flow cytometric analysis
PBMCs were isolated by density gradient centrifugation using Lympholyte-H (Cedarlane Laboratories, Hornby, Ontario, Canada) and immediately stained for KIR expression. Stained cells were fixed with 1% paraformaldehyde in PBS and analysed within 24 h. Flow cytometric analyses were performed using a FACSCanto (BD Biosciences, Franklin Lakes, NJ) and data were analysed with FACSDiva 6.1.3 software (BD Biosciences).
Percentages of cells expressing KIR3DL2 and KIR3DL1 and KIR receptor density were evaluated on CD3À/CD56+ NK and CD3+/CD4+ T cells. Briefly, for each sample, the mean fluorescence channel was expressed as Relative Channel Number on a linear scale, compared with five different standards of beads coated with defined mouse antibodies and converted into Antibody Binding Capacity (ABC) (DAKO Denmark). Saturating concentrations of primary and secondary antibodies were used. Fluorescence correlates with the number of bound primary antibody molecules on the cells and on the beads and ABC units correspond to the number of binding sites [33] .
Data analysis
Values are expressed as mean percentages ± S.D. positive cells and as mean cell surface antigen density in ABC units. Differences between AS and HCs were analysed by one-way analyses of variance (ANOVA) with a Bonferroni post-test and a two-tailed unpaired t-test with Welch's correction. Statistical analysis was performed using Prism 5.0 software (GraphPad Inc.).
Results
HLA-B*27:05 forms more cell surface FHC forms than HLA-B*27:09
The specificities of anti-HLA-B27 and anti-HLA-class I antibodies used in this study are summarized in Table 1 . The ME1 antibody recognizes b2m-associated HLA-B27, whereas W6/32 has been reported to recognize both b2m-associated and b2m-free forms of HLA-B27 and other HLA class I [30, 32, 34] . HC10 antibody binds to HLA-B27 and other b2m-free HLA class I heavy chains and HD6 antibody recognizes dimeric and multimeric forms of HLA-B27 b2m-FHC [23, 29] . We first compared levels of expression of B27 b2m-FHC on 221 cells which expressed comparable levels of HLA-B*27:05 or HLA-B*27:09 of ME1-and W6/32-reactive B27 by FACS analysis ( Fig. 1A and B) . Both HC10 and HD6 antibodies stained 221B*27:05 more strongly than 221B*27:09 cells ( Fig. 1A and B) .
Next we immunoprecipitated HC10-reactive class I heavy chains from surface biotinylated 221B*27:05 and 221B*27:09 cells. Immunoprecipitates were resolved by SDS-PAGE and analysed by western blot with HRP-conjugated streptavidin or HRP-conjugated HC10 (Fig. 1C) . Increased quantities of dimers and multimeric FHC forms were detectable in immunoprecipitates from 221B*27:05 cells compared with 221B*27:09 cells (Fig. 1C) . In the presence of dithiothreitol, higher molecular weight forms reduced to monomeric heavy chains (Fig. 1C) . W6/32 immunoprecipitated monomeric B27 heavy chains from 221B*27:05 and 221B*27:09 cells (Fig. 1C) . Western blots of whole cell lysates from 221B*27:05 and 221B*27:09 cells show equivalent levels of expression of HC10-reactive class I heavy chains ( Fig 1C) . 221B*27:05 cell lines interact more strongly with KIR3DL2 than 221B*27:09
We asked whether increased levels of expression of FHC on 221B*27:05-expressing cells compared with HLA-B*27:09-expressing cell lines would result in enhanced interactions with KIR3DL2. KIR3DL2CD3"-expressing Jurkat T reporter cells produce more IL-2 when stimulated with B27-expressing B cell lines compared with cells expressing other HLA class I [22] . KIR3DL2CD3"-expressing Jurkat reporter cells consistently produced more IL-2 when stimulated with HLA-B*27:05-expressing 221 cells compared with stimulation with HLA-B*27:09-expressing cells ( Fig. 2A) . KIR3DL2CD3"-reporter cell B27 interactions were inhibited by FHC and dimer reactive antibodies HC10 and HD6, respectively, and by W6/32 but not by isotype control mAbs ( Fig. 2A) . W6/32 has been reported to bind to some forms of b2m-free HLA class I including HLA-B27. ME1 antibody which binds to b2m-associated HLA-B27 had no effect ( Fig. 2A) .
We studied survival of KIR3DL2-expressing cells stimulated with transduced 221 cells for 5 days. Viable NK cells do not stain with Annexin V and dead stains. 221B*27:05 cells stimulated greater survival of KIR3DL2-expressing NK cells compared with 221B*27:09 cells (Fig. 2B and  C) . NK cell survival was reduced by stimulation in the presence of HC10, W632 and anti-KIR3DL2 (DX31) mAbs ( Fig. 2B and C) .
HLA-B*27:05 forms more heavy chain homodimer (B27 2 ) in vitro than HLA-B*27:09
In order to determine whether increased dimer formation is an inherent property of HLA-B*27:05, we next asked whether HLA-B*27:05 and HLA-B*27:09 subtypes differed in their ability to form heavy chain homodimers in vitro.
Identical quantities of HLA-B*27:05 and HLA-B*27:09 heavy chains were refolded with b2m and B27-binding peptide or without b2m and the yield and purity of resulting B27 heterodimers and dimers assessed biochemically by FPLC and SDS PAGE. Fig. 3A shows representative FPLC plots of refolded protein from HLA-B*27:05 and HLA-B*27:09, folded in parallel in the presence of b2m and peptide. A panel of HLA-B*27:05-and HLA-B*27:09-specific peptides and shared epitopes (summarized in Materials and methods section) were used. Peaks corresponding to homodimers and heterodimers, defined by SDS PAGE, were quantified by gel exclusion chromatography. Refolds were performed for seven peptides and repeated up to five times. A representative purification is shown in Fig. 4A and the yields of dimeric and heterodimeric protein, expressed as a proportion of total dimeric and heterodimeric protein, are summarized in Fig. 3B . Although we consistently observed heterodimers, in some refolds with HLA-B*27:09 dimer peaks were absent (results not shown). HLA-B*27:05 consistently yielded more B27 dimer compared with HLA-B*27:09.
HLA-B*27:05 heavy chains folded in the absence of b2m consistently yielded more B27 dimer compared with HLA-B*27:09 (Fig. 3C) . Recombinant HLA-B*27:05 and HLA-B*27:09 dimers bound equivalently strongly to HC10 antibody in ELISA (Fig. 3D) . In contrast HLA-B*27:05 dimers bound more strongly to HD6 antibody compared with HLA-B*27:09 dimers in ELISA (Fig. 3D) . As previously observed neither HLA-G dimers nor HLA-B27 heterodimers bound to HD6 antibody ( Fig. 3D and results not shown).
Recombinant HLA-B*27:05 and HLA-B*27:09 dimer tetramers bind similarly to KIR3DL1, KIR3DL2 and LILRB2; HLA-B*27:05 and HLA-B*27:09 heterodimers bind differently to KIR3DL1 Differences in KIR3DL2 binding to HLA-B*27:05 and HLA-B*27:09 could occur as a consequence of differences in their propensity to form B27 dimers and other FHC species and/or differences in their interaction with KIR receptors. In order to address whether HLA-B*27:05 and HLA-B*27:09 bound differently to immune receptors, we studied the ability of HLA-B*27:05 and HLA-B*27:09 dimer and heterodimer tetramers to stain KIR3DL1/2- (Fig. 4A) . Neither HLA-B*27:05 nor HLA-B*27:09 dimer tetramers bound LILRB1-transduced Baf3 cells (results not shown).
HLA-B*27:05 and HLA-B*27:09 dimers bound KIR3DL1 and KIR3DL2 transfectants similarly (Fig. 4B) .
HLA-B*27:05 heterodimer tetramers formed with FluNP and Gag epitopes stain KIR3DL1 transfectants. In contrast HLA-B*27:09 heterodimer tetramers complexed with these epitopes did not stain KIR3DL1-transfected cells as strongly as HLA-B*27:05 heterodimers, although these tetramers nevertheless stained LILRB1/ILT2-transfected cells equivalently ( Fig. 4C and D) .
Increased proportions of peripheral blood NK and CD4 T cells express KIR3DL2 in HLA-B*27:05+ AS patients compared with healthy B*27:05+, B*27:09+ and B27 negative controls
We have previously demonstrated increased proportions of peripheral blood NK and CD4 T cells expressing KIR3DL2 in HLA-B*27:05+ SpA patients compared with B27À RA, ulcerative colitis and HCs [17, 18] . Although KIR3DL2 is also expressed on CD8 T cells, we did not observe significant increases in the proportions of CD8 T cells expressing KIR3DL2 in SpA patients in these studies. Thus, we chose to focus on studying on KIR3DL2 expression by NK and CD4 T cells in this study. Our results indicated a reduced propensity of HLA-B*27:09 to form dimeric and other B27 FHC forms and decreased Fig. 5A and B) . In contrast we did not see any significant differences in the proportions of NK and CD4 T cells expressing KIR3DL1 and KIR3DS1 between each of these groups. A mean of 20.7 ± 11.9 AS NK cells expressed KIR3DL1 compared with 13.0 ± 8.9 (P = ns) HLA-B*27:05 HCs, 12.8 ± 10.7 HLA-B*27:09 HCs (P = ns) and 23.7 ± 17.7 HLA-B27 negative (P = ns) (results expressed as mean values ± 1S.D.). AS patient NK cells expressed a mean of 9301.2 ± 3175.5 ABC units KIR3DL1 compared with 7429.5 ± 4784.2 units in HLA-B*27:05 HCs (P = ns), 6027.4 ± 4082.6 units in HLA-B*27:09 HCs (P = ns) and 7512 ± 5088 units in HLA-B27 negative HCs (P = ns). 0.5% ± 0.4% AS CD4 T cells expressed KIR3DL1 compared with an aggregated mean of 0.3 ± 0.3 in the HC groups (P = ns). KIR3DS1 staining was only detected in one HLA-B*27:09 HC in this study.
Discussion
Here we show that HLA-B*27:05, which is strongly associated with SpA, forms more B27 FHC ligands for KIR3DL2 compared with HLA-B*27:09 which is not associated with disease. We detected more cell surface heavy chain dimers and FHC forms on 221B*27:05 compared with 221*27:09 cells biochemically. 221B*27:05 cells also stained more strongly than 221B*27:09 cells with HD6 antibody, which recognizes B27 FHC dimers and other FHCs [23] . Western blots showed that 221B*27:05 and 221B*27:09 cells expressed equivalent amounts of class I heavy chains in cell lysates. Moreover 221B*27:05 and 221B*27:09 cells expressed similar levels of cell surface ME1 and W6/32-reactive B27. These findings support previous preliminary work showing increased proportions of heavy chain dimers on the surface of 221B*27:05 cells compared with 221B*27:09 cells [35] .
We have previously shown that B27 FHC is a ligand for KIR3DL2 [3, 22] . Consistent with 221B*27:05 cells expressing more cell surface FHC forms than 221B*27:09, 221B*27:05-expressing cells stimulated KIR3DL2CD3e reporter cells to a greater extent than 221B*27:09. Moreover KIR3DL2 ligation by HLA-B*27:05 promoted leucocyte survival to a greater degree than HLA-B*27:09.
Reduced interactions with KIR3DL2 could result from decreased cell surface ligand density and/or differences in the strength of ligand binding to these receptors. HLA-B*27:05 and HLA-B*27:09 dimer tetramers bound HLA-B*27:09 heterodimer tetramers bound more weakly or did not bind to KIR3DL1 compared with HLA-B*27:05 heterodimers with the same peptide. The amino acid change of aspartic acid in HLA-B*27:05 to histidine in HLA-B*27:09 at position 116 influences the conformation of bound peptide and recognition by CD8 T cells [36] . KIR3DL1 recognition of HLA-Bw4 is dependent on the sequence of the C-terminal positions 7 and 8 of bound peptide [13] . Differences in the preferred C-terminal anchor and the C-terminal conformations of bound peptide between HLA-B*27:05 and HLA-B*27:09 could thus affect KIR3DL1 recognition.
HLA-B*27:05+ SpA patients had increased proportions of KIR3DL2-expressing peripheral blood NK and CD4 T cells compared with healthy HLA-B*27:05+, HLA-B*27:09+ and B27À controls. Although we have previously shown increased KIR3DL2 expression on leucocytes from B27+SpA patients compared with leucocytes from arthritis and B27 negative HCs, we did not study expression on HLA-B*27:09 controls [17, 18] . KIR3DL2 + CD4 Th17 cells, highly enriched for the expression of Th17 phenotypic markers, are expanded in SpA patients [18] . Increased levels of HLA-B27 FHC dimers and FHC are expressed by monocytes from SpA patients [23, 3739] . Thus increased expression of B27 FHC ligands for immune receptors such as KIR3DL2 in SpA patients with HLA-B*27:05 could promote the survival of proinflammatory leucocytes.
Our results suggest that the increased binding of HLA-B*27:05 FHC to KIR3DL2 is primarily due to increased formation of FHC compared with HLA-B*27:09. HLA-B*27:05 and HLA-B*27:09 dimer tetramers bound similarly to KIR and LILRB2 receptors. HLA-B*27:05 shows an increased propensity to form dimers compared with HLA-B*27:09. The reactive cysteine 67 is critical for B27 heavy chain dimer formation [5] . Differences in residues at position 116 of the class I heavy chain affect both the reactivity of cysteine 67 and the way in which these two alleles fold and unfold and could affect dimer and FHC formation [5, 40, 41] .
B27 FHC forms including B27 dimers form more readily from b2m-associated HLA-B27 heterodimers suboptimally loaded with peptide [5] . It is possible that HLA-B*27:05 is less stringent in the optimization of peptide cargo compared with HLA-B*27:09. Thus, the increased instability of b2m-associated HLA-B*27:05 compared with HLA-B*27:09 could lead to the formation of more B27 FHC forms in disease.
Here we show that disease-associated HLA-B*27:05 forms more B27 heavy chain dimer and FHC in vitro and on transfected cells than HLA-B*27:09, which is not associated with disease. Increased expression of cell surface B27 FHC forms by HLA-B*27:05 correlates with stronger interaction with KIR3DL2 compared with HLAB*27:09. HLA-B*27:05 + AS leucocytes have increased proportions of KIR3DL2. Thus, the increased propensity of HLA-B*27:05 to form FHC ligand compared with HLA-B*27:09 results in enhanced survival of KIR3DL2-expressing leucocytes and could contribute to the differential association of these B27 alleles with AS. 
